- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03386526
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
August 12, 2022 updated by: Ascentage Pharma Group Inc.
A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies
APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP) antagonist.
APG-1387 has shown strong dose- and schedule-dependent antitumor activities in multiple human cancer xenograft models, APG-1387 also demonstrates its synergistic effect in combination with immune checkpoint inhibitor anti-PD-1 antibody, and such a combinatory effect was further enhanced by chemotherapeutic agent.
A total of 35 patients with advanced solid tumors or lymphomas have been treated with APG-1387 in two Phase I dose-escalation studies in Australia and in China.
Ten dose levels have been tested ranging from 0.3 mg to 45 mg in these two studies.
Based on the preliminary results, APG-1387 is well-tolerated at the dose levels evaluated to date.
APG-1387 is intended for the treatment of patients with advanced solid tumors and hematologic malignancies.
After establishing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several Ib /II studies will be implemented accordingly to further access the antitumor effects of APG-1387 in combination with either pembrolizumab or the chemotherapeutic agents.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Angela Kaiser
- Phone Number: 9192607547
- Email: angela.kaiser@ascentage.com
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Paul Swiecicki, MD
- Email: pswiecicki@uofm.edu
-
Principal Investigator:
- Paul Swiecicki, MD
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Start Midwest
-
Principal Investigator:
- Nehal Lakhani, MD, PhD
-
Contact:
- Nehal Lakhani, MD
- Phone Number: 616-954-5554
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- The START Center for Cancer Care
-
Principal Investigator:
- Drew Rasco, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed solid tumor or hematological malignancies
- Life expectancy ≥ 3 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- Corrected QT interval (QTc) ≤ 450 ms in males, and ≤ 470 ms in females
- Adequate hematologic function
- International normalized ratio (INR), prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5 x upper limit of normal (ULN)
- Adequate renal and liver function
- Willingness to use contraception
- Ability to understand and willingness to sign a written informed consent form
- Willingness and ability to comply with study procedures and follow-up examination
- Have provided tissue for biomarker analysis from a newly or recently-obtained biopsy of a tumor lesion not previously irradiated
Exclusion Criteria:
- Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to entering the study
- Received hormonal, biologic (< 2 half-lives), small molecule targeted therapies or other anti-cancer therapy within 21 days of study entry
- Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days of study entry
- Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Patients who have received prior radiotherapy for previous brain metastasis must have discontinued steroids for 14 days prior to study entry and be clinically stable
- Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia
- Requirement for corticosteroid treatment, with the exception of megestrol, local use of steroid
- Use of therapeutic anticoagulants
- International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≥ 1.5 x ULN
- Concurrent treatment with an investigational agent or device within 28 days prior to the first dose of therapy
- Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry
- Neurologic instability per clinical evaluation due to tumor involvement of the central nervous system (CNS)
- History of Bell's palsy
- Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation
- Active infection requiring systemic antibiotic/ antifungal medication
- Known or suspected Wilson's Disease
- Prior treatment with IAP inhibitors
- History of hypersensitivity to paclitaxel, or any therapeutic antibody
- Has an active autoimmune disease, or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents
- Is on chronic systemic steroid therapy
- Has received a live vaccine within 30 days prior to first dose
- Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: APG-1387 for Injection
APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
|
Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 18-24 months
|
Patients with APG-1387 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.03
|
18-24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-tumor effects of APG-1387 as a single agent
Time Frame: 18-24 months
|
Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1 or the Revised Response Criteria for Malignant Lymphoma
|
18-24 months
|
Pharmacokinetic evaluation
Time Frame: 18-24 months
|
Maximum plasma concentration (Cmax) will be assessed in the patients treated with APG-1387
|
18-24 months
|
Anti-tumor effects of APG-1387 in combination with pembrolizumab or combination with paclitaxel and carboplatin in patients with advanced solid tumors
Time Frame: 18-24 months
|
Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1 or the Revised Response Criteria for Malignant Lymphoma
|
18-24 months
|
Preliminary biomarker assessment
Time Frame: 18-24 months
|
Tumor biopsy and peripheral blood sample at baseline and 15-21 days after administration of APG-1387 alone or in combination with systemic anti-cancer therapy
|
18-24 months
|
Pharmacokinetic evaluation
Time Frame: 18-24 months
|
Area under the plasma concentration versus time curve (AUC) of APG-1387 will be assessed on patients treated with APG-1387
|
18-24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2017
Primary Completion (Anticipated)
October 31, 2022
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
December 13, 2017
First Submitted That Met QC Criteria
December 21, 2017
First Posted (Actual)
December 29, 2017
Study Record Updates
Last Update Posted (Actual)
August 16, 2022
Last Update Submitted That Met QC Criteria
August 12, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APG-1387-US-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors or Hematologic Malignancies
-
iOMEDICO AGBristol-Myers Squibb; Roche Pharma AGCompletedAdvanced Solid Tumors or Hematologic MalignanciesGermany
-
Suzhou Junjing BioSciences Co., Ltd.RecruitingAdvanced Solid Tumors | Advanced Hematologic MalignanciesChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors and Hematologic MalignanciesChina
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
AstraZenecaCompletedCancer | Solid Tumors | Advanced Solid MalignanciesJapan
-
AstraZenecaTerminatedCancer | Solid Tumors | Advanced Solid MalignanciesJapan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Solid Tumors and Hematological Malignancies
-
AstraZenecaTerminatedSolid Tumors | Advanced Solid Malignancies | Cancer,United States
-
Washington University School of MedicineCompletedSolid Tumors | Advanced Gastrointestinal MalignanciesUnited States
-
Novartis PharmaceuticalsCompletedSolid Tumors | Advanced MalignanciesUnited States
Clinical Trials on APG-1387 for Injection
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.CompletedChronic Hepatitis BChina
-
Ascentage Pharma Group Inc.Recruiting
-
Ascentage Pharma Group Inc.CompletedSmall Cell Lung Cancer | Solid TumorUnited States
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.TerminatedSmall Cell Lung Cancer and Other Solid TumorsChina
-
Ascentage Pharma Group Inc.Recruiting
-
Ascentage Pharma Group Inc.RecruitingHepatitis B | HBV | Chronic Hep BChina
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingEGFR Positive Non-small Cell Lung CancerChina
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States